Mesoblast Limited (NASDAQ:MESO - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 419,400 shares were traded during trading, a decline of 21% from the previous session's volume of 532,140 shares.The stock last traded at $17.18 and had previously closed at $17.90.
Analyst Ratings Changes
A number of brokerages have recently commented on MESO. Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. Finally, Piper Sandler raised their price target on Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $13.50.
Check Out Our Latest Analysis on Mesoblast
Mesoblast Stock Down 4.0 %
The stock's 50-day simple moving average is $13.07 and its 200 day simple moving average is $9.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.
Institutional Investors Weigh In On Mesoblast
A number of institutional investors have recently added to or reduced their stakes in the business. Signaturefd LLC raised its stake in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock worth $45,000 after buying an additional 3,099 shares in the last quarter. GAMMA Investing LLC grew its holdings in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after acquiring an additional 1,213 shares during the period. Perkins Coie Trust Co raised its position in Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock worth $94,000 after acquiring an additional 1,500 shares in the last quarter. Rathbones Group PLC acquired a new stake in Mesoblast in the second quarter valued at $95,000. Finally, XTX Topco Ltd purchased a new stake in shares of Mesoblast during the 2nd quarter worth $103,000. Hedge funds and other institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
